Nothing Special   »   [go: up one dir, main page]

DE60322359D1 - Imidazopyridinderivate als kinaseinhibitoren - Google Patents

Imidazopyridinderivate als kinaseinhibitoren

Info

Publication number
DE60322359D1
DE60322359D1 DE60322359T DE60322359T DE60322359D1 DE 60322359 D1 DE60322359 D1 DE 60322359D1 DE 60322359 T DE60322359 T DE 60322359T DE 60322359 T DE60322359 T DE 60322359T DE 60322359 D1 DE60322359 D1 DE 60322359D1
Authority
DE
Germany
Prior art keywords
sub
group selected
kinase inhibitors
imidazopyridine derivatives
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60322359T
Other languages
English (en)
Inventor
Nicholas Bailey
Mark James Bamford
Stephen Garland
Krista B Goodman
Cui Haifeng
Mark A Hilfiker
Dennis Lee
Terence Aaron Panchal
Robert A Stavenger
David Matthew Wilson
Jason Witherington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60322359D1 publication Critical patent/DE60322359D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60322359T 2002-03-22 2003-03-21 Imidazopyridinderivate als kinaseinhibitoren Expired - Lifetime DE60322359D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0206860.9A GB0206860D0 (en) 2002-03-22 2002-03-22 Compounds
PCT/GB2003/001205 WO2003080610A1 (en) 2002-03-22 2003-03-21 Imidazopyridine derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
DE60322359D1 true DE60322359D1 (de) 2008-09-04

Family

ID=9933560

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60322359T Expired - Lifetime DE60322359D1 (de) 2002-03-22 2003-03-21 Imidazopyridinderivate als kinaseinhibitoren

Country Status (9)

Country Link
US (1) US7348339B2 (de)
EP (1) EP1490367B1 (de)
JP (1) JP2005526802A (de)
AT (1) ATE402174T1 (de)
AU (1) AU2003215753A1 (de)
DE (1) DE60322359D1 (de)
ES (1) ES2309330T3 (de)
GB (1) GB0206860D0 (de)
WO (1) WO2003080610A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2492964C (en) * 2002-07-24 2012-07-17 Qlt Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
EP1606266A4 (de) * 2003-03-21 2008-06-25 Smithkline Beecham Corp Chemische verbindungen
AR045134A1 (es) * 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
WO2005012269A1 (ja) * 2003-08-05 2005-02-10 Ajinomoto Co., Inc. 新規アゾール化合物
US7547779B2 (en) 2003-10-06 2009-06-16 Glaxo Group Limited Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
EP1670466A4 (de) * 2003-10-06 2007-04-25 Glaxo Group Ltd Zubereitung von 1,6,7-trisubstituierten azabenzimidazolen als kinasehemmer
WO2005037198A2 (en) * 2003-10-06 2005-04-28 Glaxo Group Limited Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
CA2580852A1 (en) 2004-09-21 2006-03-30 Synta Pharmaceutical Corp. Compounds for inflammation and immune-related uses
JP2008515935A (ja) * 2004-10-13 2008-05-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 腫瘍疾病の治療のためのチロシンキナーゼ阻害剤としてのフェニル尿素誘導体
AU2005309616A1 (en) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
CA2595157A1 (en) * 2005-01-21 2006-07-27 Schering Corporation Imidazole and benzimidazole derivatives useful as histamine h3 antagonists
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
PE20061378A1 (es) * 2005-04-20 2006-12-03 Smithkline Beecham Corp INHIBIDORES DE LA ACTIVIDAD DE Akt
GB0512844D0 (en) * 2005-06-23 2005-08-03 Novartis Ag Organic compounds
US20090215857A1 (en) * 2005-09-13 2009-08-27 Pfizer Products Inc. Therapeutic Pyrrolidines
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
US8022075B2 (en) 2005-11-30 2011-09-20 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
CA2629342A1 (en) * 2005-12-22 2007-07-05 Alcon Research, Ltd. (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
RS54542B1 (en) * 2006-08-02 2016-06-30 Cytokinetics, Inc. CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INCLUDING IMIDAZOPYRIMIDINE
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008121333A1 (en) * 2007-03-30 2008-10-09 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
CA2703653A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives -083
CN101983061A (zh) * 2008-02-04 2011-03-02 赛特凯恩蒂克公司 某种化学物质、组合物和方法
WO2009138229A1 (en) * 2008-05-16 2009-11-19 Cellzome Ag Methods for the identification of parp interacting molecules and for purification of parp proteins
CA2743134A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
HUE036068T2 (hu) 2008-12-19 2018-06-28 Vertex Pharma ATR kináz gátlószereiként alkalmazható pirazinszármazékok
US8592425B2 (en) 2009-01-16 2013-11-26 Merck Sharp & Dohme Corp. Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors
PE20120003A1 (es) * 2009-01-30 2012-02-12 Glaxosmithkline Llc Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino
CA2753208C (en) 2009-02-20 2018-08-21 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
EP2401364B1 (de) * 2009-02-27 2015-04-22 Cellular Dynamics International, Inc. Differenzierung pluripotenter zellen
WO2011034741A1 (en) * 2009-09-15 2011-03-24 Merck Sharp & Dohme Corp. Imidazopyridin-2-one derivatives
EP2519522B1 (de) * 2009-12-30 2014-09-24 ArQule, Inc. Substituierte imidazopyridinyl-aminopyridin-verbindungen
MX2012013081A (es) 2010-05-12 2013-05-09 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
WO2011143399A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
MX2012013082A (es) 2010-05-12 2013-05-09 Vertex Pharma Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr.
JP2013526539A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用なピラジン
EP2569287B1 (de) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Verbindungen als hemmer der atr-kinase
JP2013529200A (ja) 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2011163527A1 (en) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
JP6076258B2 (ja) 2010-11-12 2017-02-08 ジョージタウン ユニヴァーシティ 上皮細胞の不死化および使用法
MX2013011450A (es) 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
JP2014520161A (ja) 2011-06-22 2014-08-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
AU2012272937B2 (en) 2011-06-24 2016-09-29 Arqule, Inc Substituted imidazopyridinyl-aminopyridine compounds
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
CN102295594B (zh) * 2011-07-12 2016-01-20 上海医药工业研究院 4-n-取代-1-(3-甲氧基丙基)-4-哌啶胺类化合物及制备和应用
CN104039148A (zh) 2011-07-13 2014-09-10 赛特凯恩蒂克公司 组合als疗法
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CA3089792C (en) 2011-09-30 2023-03-14 Vertex Pharmaceuticals Incorporated Treating non-small cell lung cancer with atr inhibitors
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
RU2677292C2 (ru) 2011-09-30 2019-01-16 Вертекс Фармасьютикалз Инкорпорейтед Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
AU2012315611A1 (en) 2011-09-30 2014-04-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776420A1 (de) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazinverbindungen als atr-kinaseinhibitoren
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
EP2776422A1 (de) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Als atr-kinasehemmer nützliche verbindungen
US20140044802A1 (en) 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
US9260696B2 (en) 2012-04-24 2016-02-16 Dan S. Kaufman Method for developing natural killer cells from stem cells
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US9226922B2 (en) 2012-09-28 2016-01-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
WO2014062604A1 (en) 2012-10-16 2014-04-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
KR102213986B1 (ko) 2012-12-07 2021-02-09 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
GB201304526D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
CN108997225A (zh) 2013-03-14 2018-12-14 特雷罗药物股份有限公司 Jak2和alk2抑制剂及其使用方法
CA3143449A1 (en) 2013-03-14 2014-09-25 The Regents Of The University Of California In vitro production of medial ganglionic eminence precursor cells
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
CN105377837B (zh) 2013-05-14 2017-08-04 活跃生物技术有限公司 用作s100‑抑制剂的n‑(杂芳基)磺酰胺衍生物
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
SI3077397T1 (sl) 2013-12-06 2020-02-28 Vertex Pharmaceuticals Inc. 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati
WO2015164479A1 (en) * 2014-04-22 2015-10-29 Arqule, Inc. Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
US9670215B2 (en) 2014-06-05 2017-06-06 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
MX2016016115A (es) 2014-06-17 2017-03-08 Vertex Pharma Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr).
EP3161127A4 (de) 2014-06-27 2018-06-06 The Regents of the University of California Kultivierte säugerlimbusstammzellen, verfahren zur erzeugung davon und verwendungen davon
WO2016085765A1 (en) 2014-11-25 2016-06-02 President And Fellows Of Harvard College Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
MX2017012206A (es) 2015-04-03 2018-01-24 Propagenix Inc Proliferacion ex vivo de celulas epiteliales.
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
EP3347450B1 (de) 2015-09-11 2021-03-17 Propagenix Inc. Ex-vivo-proliferation von epithelzellen
WO2017059357A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
WO2017066705A1 (en) * 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US20200385406A1 (en) * 2017-12-22 2020-12-10 Southern Research Institute Substituted heterocyclic-pyridinones as hiv-1 nef-hck inhibitors
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
US20210189351A1 (en) 2018-08-20 2021-06-24 Propagenix Inc. Epithelial cell spheroids
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
CA3115472A1 (en) 2018-10-05 2020-04-09 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with apj receptor activity
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
CN111732584B (zh) * 2019-03-25 2024-02-27 复旦大学 二芳基取代稠杂环类化合物及其制备方法和在制药中的用途
JP2023522784A (ja) 2020-04-27 2023-05-31 ノバルティス アーゲー 眼細胞療法のための方法及び組成物
CA3235384A1 (en) 2021-10-18 2023-04-27 Takahiro Ochiya Compositions and methods of use thereof for treating liver fibrosis
AU2022369459A1 (en) 2021-10-22 2024-05-30 Evia Life Sciences Inc. Methods for making extracellular vesicles, and compositions and methods of use thereof
WO2024083237A1 (en) * 2022-10-20 2024-04-25 Impact Therapeutics (Shanghai) , Inc Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3722992A1 (de) * 1987-07-11 1989-01-19 Thomae Gmbh Dr K Neue imidazo-pyridine und purine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ATE359822T1 (de) * 1996-08-12 2007-05-15 Mitsubishi Pharma Corp Medikamente enthaltend rho-kinase inhibitoren
WO2000009162A1 (fr) * 1998-08-17 2000-02-24 Senju Pharmaceutical Co., Ltd. Medicaments preventifs/curatifs pour le glaucome
JP2000063274A (ja) * 1998-08-20 2000-02-29 Yoshitomi Pharmaceut Ind Ltd 喘息抑制用吸入剤
CN1358102A (zh) * 1999-04-22 2002-07-10 三菱制药株式会社 血管狭窄预防治疗药
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2001057018A1 (en) 2000-02-02 2001-08-09 Abbott Laboratories Azaazulene inhibitors of p38 map kinase and tnf-alpha
SI1270570T1 (sl) * 2000-03-16 2006-10-31 Mitsubishi Pharma Corp Amidne spojine in njihova uporaba
ES2437391T3 (es) * 2002-02-06 2014-01-10 Vertex Pharmaceuticals, Inc. Compuestos de heteroarilo útiles como inhibidores de GSK-3
EP1670466A4 (de) * 2003-10-06 2007-04-25 Glaxo Group Ltd Zubereitung von 1,6,7-trisubstituierten azabenzimidazolen als kinasehemmer

Also Published As

Publication number Publication date
ES2309330T3 (es) 2008-12-16
AU2003215753A1 (en) 2003-10-08
US20050197328A1 (en) 2005-09-08
EP1490367B1 (de) 2008-07-23
US7348339B2 (en) 2008-03-25
GB0206860D0 (en) 2002-05-01
EP1490367A1 (de) 2004-12-29
ATE402174T1 (de) 2008-08-15
JP2005526802A (ja) 2005-09-08
WO2003080610A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
SE0202463D0 (sv) Novel compounds
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
WO2003013484A3 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
NO20070432L (no) Pyrimidinureaderivater som kinaseinhibitorer
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20066055L (no) Pyridinderivater
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
DE60226469D1 (de) Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
NO20085087L (no) Nye heterocykliske forbindelser
DE602004012758D1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
DK0734383T3 (da) Cykliske amidderivater som neurokinin-A-antagonister
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition